Serovar D and E of serogroup B induce highest serological responses in urogenital Chlamydia trachomatis infections

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Verweij, Stephan P ^a   Lanjouw, Esmée ^b   Bax, Caroline J ^a,c   Quint, Koen D ^d,e   Oostvogel, Paul M ^c   Dörr, P J ^c   Pleijster, Jolein ^a   de Vries, Henry J C ^f,g   Peters, Remco P H ^h,i   Ouburg, Sander ^a   Morré, Servaas A ^a,j  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Medisch Centrum Voor Dansers en Musici   (Netherlands)

^d DDL DIAGNOSTIC LABORATORY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h Municipal Medical and Health Service of The Hague   (Netherlands)

ⁱ ANOVA HEALTH INSTITUTE   (South Africa)

^j MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

Antibodies; Chlamydia trachomatis; IgG; Serogroup; Serological response; Serovar

Indexed keywords

IMMUNOGLOBULIN G;

ANTIBODY TITER; ARTICLE; CHLAMYDIASIS; CONTROLLED STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; SEROLOGY; SEROTYPE; UROGENITAL TRACT INFECTION; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; MICROBIOLOGY; NETHERLANDS; PREVALENCE; UROGENITAL TRACT DISEASE;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMALE UROGENITAL DISEASES; GENOTYPE; HUMANS; MALE; MALE UROGENITAL DISEASES; NETHERLANDS; PREVALENCE; SEROGROUP;

EID: 84892460227     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-3     Document Type: Article

References (31)

1. Morré SA, Spaargaren J, Ossewaarde JM, Land JA, Bax CJ, Dorr PJ, Oostvogel PM, Vanrompay D, Savelkoul PH, Pannekoek Y, et al. Description of the ICTI consortium: an integrated approach to the study of Chlamydia trachomatis infection. Drugs Today (Barc) 2006, 42(Suppl A):107-114.
2. Brunelle BW, Sensabaugh GF. The ompA gene in Chlamydia trachomatis differs in phylogeny and rate of evolution from other regions of the genome. Infect Immun 2006, 74:578-585. 10.1128/IAI.74.1.578-585.2006, 1346613, 16369014.
3. Dean D, Millman K. Molecular and mutation trends analyses of omp1 alleles for serovar E of Chlamydia trachomatis. Implications for the immunopathogenesis of disease. J Clin Invest 1997, 99:475-483. 10.1172/JCI119182, 507821, 9022081.
4. Morré SA, Ossewaarde JM, Lan J, van Doornum GJ, Walboomers JM, MacLaren DM, Meijer CJ, van den Brule AJ. Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. J Clin Microbiol 1998, 36:345-351. 104540, 9466739.
5. Meijer A, Morré SA, van den Brule AJ, Savelkoul PH, Ossewaarde JM. Genomic relatedness of Chlamydia isolates determined by amplified fragment length polymorphism analysis. J Bacteriol 1999, 181:4469-4475. 103574, 10419941.
6. Morré SA, Moes R, van Valkengoed IG, Boeke JP, van Eijk JT, Meijer CJ, van den Brule AJ. Genotyping of Chlamydia trachomatis in urine specimens will facilitate large epidemiological studies. J Clin Microbiol 1998, 36:3077-3078. 105118, 9738074.
7. Molano M, Meijer CJ, Morré SA, Pol R, van den Brule AJ. Combination of PCR targeting the VD2 of omp1 and reverse line blot analysis for typing of urogenital Chlamydia trachomatis serovars in cervical scrape specimens. J Clin Microbiol 2004, 42:2935-2939. 10.1128/JCM.42.7.2935-2939.2004, 446312, 15243041.
8. Quint KD, van Doorn LJ, Kleter B, de Koning MN, van den Munckhof HA, Morré SA, ter Harmsel B, Weiderpass E, Harbers G, Melchers WJ, et al. A highly sensitive, multiplex broad-spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for rapid detection and identification of Chlamydia trachomatis serovars. J Mol Diagn 2007, 9:631-638. 10.2353/jmoldx.2007.070011, 2049059, 17872971.
9. White JA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis 2009, 22:57-66. 10.1097/QCO.0b013e328320a8ae, 19532081.
10. Byrne GI. Chlamydia trachomatis strains and virulence: rethinking links to infection prevalence and disease severity. J Infect Dis 2010, 201(Suppl 2):S126-S133. 2878587, 20470049.
11. van Duynhoven YT, Ossewaarde JM, Derksen-Nawrocki RP, van der Meijden WI, van de Laar MJ. Chlamydia trachomatis genotypes: correlation with clinical manifestations of infection and patients' characteristics. Clin Infect Dis 1998, 26:314-322. 10.1086/516291, 9502448.
12. Morré SA, Rozendaal L, van Valkengoed IG, Boeke AJ, van Voorst Vader PC, Schirm J, de Blok S, van den Hoek JA, van Doornum GJ, Meijer CJ, et al. Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations?. J Clin Microbiol 2000, 38:2292-2296. 86784, 10834991.
13. Lampe MF, Wong KG, Stamm WE. Sequence conservation in the major outer membrane protein gene among Chlamydia trachomatis strains isolated from the upper and lower urogenital tract. J Infect Dis 1995, 172:589-592. 10.1093/infdis/172.2.589, 7622913.
14. Workowski KA, Stevens CE, Suchland RJ, Holmes KK, Eschenbach DA, Pettinger MB, Stamm WE. Clinical manifestations of genital infection due to Chlamydia trachomatis in women: differences related to serovar. Clin Infect Dis 1994, 19:756-760. 10.1093/clinids/19.4.756, 7803644.
15. Lyons JM, Ito JI, Pena AS, Morré SA. Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarum. J Clin Pathol 2005, 58:397-401. 10.1136/jcp.2004.021543, 1770636, 15790704.
16. Akande VA, Hunt LP, Cahill DJ, Caul EO, Ford WC, Jenkins JM. Tubal damage in infertile women: prediction using chlamydia serology. Hum Reprod 2003, 18:1841-1847. 10.1093/humrep/deg347, 12923136.
17. Verweij SP, Bax CJ, Quint KD, Quint WG, van Leeuwen AP, Peters RP, Oostvogel PM, Mutsaers JA, Dorr PJ, Pleijster J, et al. Significantly higher serologic responses of Chlamydia trachomatis B group serovars versus C and I serogroups. Drugs Today (Barc) 2009, 45(Suppl B):135-140.
18. Ouburg S, Spaargaren J, den Hartog JE, Land JA, Fennema JS, Pleijster J, Pena AS, Morré SA. The CD14 functional gene polymorphism -260C > T is not involved in either the susceptibility to Chlamydia trachomatis infection or the development of tubal pathology. BMC Infect Dis 2005, 5:114. 10.1186/1471-2334-5-114, 1351185, 16368002.
19. Haasnoot A, Koedijk FD, Op de Coul ELM, Gotz HM, van der Sande MA, van den Broek IV. Comparing two definitions of ethnicity for identifying young persons at risk for chlamydia. Epidemiol Infect 2012, 140:951-958. 10.1017/S0950268811001336, 21767454.
20. Spaargaren J, Verhaest I, Mooij S, Smit C, Fennema HS, Coutinho RA, Peña AS, Morré SA. Analysis of Chlamydia trachomatis serovar distribution changes in the Netherlands (1986-2002). Sex Transm Infect 2004, 80:151-152. 10.1136/sti.2003.006395, 1744799, 15054183.
21. Mardh P-A, Paavonen J, Puolakkainen M. Chlamydia 1989, New York: Plenum Medical Book Company.
22. Mann-Whitney U Test. http://elegans.swmed.edu/~leon/stats/utest.html.
23. Morré SA, Munk C, Persson K, Kruger-Kjaer S, van Dijk R, Meijer CJ, van den Brule AJ. Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol 2002, 40:584-587. 10.1128/JCM.40.2.584-587.2002, 153365, 11825974.
24. Horner PJ, Wills GS, Reynolds R, Johnson AM, Muir DA, Winston A, Broadbent AJ, Parker D, McClure MO. Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study. Sex Transm Infect 2013, 89:398-403. 10.1136/sextrans-2011-050386, 23430706.
25. Land JA, van Bergen JE, Morré SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010, 16:189-204. 10.1093/humupd/dmp035, 19828674.
26. Quint KD, Bom RJ, Bruisten SM, van Doorn LJ, Nassir HN, Melchers WJ, de Vries HJ, Morré SA, Quint WG. Comparison of three genotyping methods to identify Chlamydia trachomatis genotypes in positive men and women. Mol Cell Probes 2010, 24:266-270. 10.1016/j.mcp.2010.04.007, 20457248.
27. Ito JI, Lyons JM, Airo-Brown LP. Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection. Infect Immun 1990, 58:2021-2023. 258764, 2341189.
28. Eckert LO, Suchland RJ, Hawes SE, Stamm WE. Quantitative Chlamydia trachomatis cultures: correlation of chlamydial inclusion-forming units with serovar, age, sex, and race. J Infect Dis 2000, 182:540-544. 10.1086/315738, 10915086.
29. Morré SA, van den Brule AJ, Rozendaal L, Boeke AJ, Voorhorst FJ, de Blok S, Meijer CJ. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002, 13(Suppl 2):12-18.
30. Molano M, Meijer CJ, Weiderpass E, Arslan A, Posso H, Franceschi S, Ronderos M, Munoz N, van den Brule AJ. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005, 191:907-916. 10.1086/428287, 15717266.
31. Dean D, Suchland RJ, Stamm WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis 2000, 182:909-916. 10.1086/315778, 10950788.